



## OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors

April 27, 2017

GAITHERSBURG, Md., April 27, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Tina S. Nova, Ph.D. has been appointed to its Board of Directors.

Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manager of Illumina's oncology business unit. From 2000 to 2014, Dr. Nova was a co-founder and director, president and chief executive officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation for nearly \$0.5 billion in 2011. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and Veracyte and is vice chairman of the board of directors for the newly formed Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children's Hospital-San Diego. Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine where she graduated with honors and a Ph.D. in Biochemistry from the University of California, Riverside.

"We are pleased to have Dr. Nova, a seasoned industry expert with a portfolio of high caliber successes, join the OpGen Board," said Evan Jones, Chairman and CEO of OpGen. "Dr. Nova's insights and experience from having built and advised successful molecular diagnostics companies will be invaluable as we continue to advance the development of our Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase to combat the rise of multidrug-resistant organisms in our hospitals and health systems."

### About OpGen

OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at [www.opgen.com](http://www.opgen.com) and follow OpGen on Twitter and LinkedIn.

Contact:

OpGen Contact:

Michael Farmer

Director, Marketing

240-813-1284

[mfarmer@opgen.com](mailto:mfarmer@opgen.com)

[InvestorRelations@opgen.com](mailto:InvestorRelations@opgen.com)

Investor and Media Contact:

MacDougall Biomedical Communications

Cammy Duong

781-591-3443

[cduong@macbiocom.com](mailto:cduong@macbiocom.com)



OpGen, Inc.